Comparison of telithromycin, a new ketolide, with erythromycin and clarithromycin for the treatment of Haemophilus influenzae pneumonia in suckling, middle aged and senescent mice

International Journal of Antimicrobial Agents

Volumn 20, Issue 3, 2002, Pages 180-185

  Thadepalli, Haragopal ^a   Chuah, See Kean ^a   Iskandar, Lucy ^a   Gollapudi, Sastry ^a  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

Haemophilus influenzae; Pneumonia; Telithromycin

Indexed keywords

CLARITHROMYCIN; ERYTHROMYCIN; SODIUM CHLORIDE; TELITHROMYCIN;

AGE; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL PNEUMONIA; BACTERIUM CULTURE; CONTROLLED STUDY; CONVALESCENCE; DRUG EFFICACY; HAEMOPHILUS INFLUENZAE; LUNG PARENCHYMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE CULTURE; TREATMENT FAILURE; TREATMENT OUTCOME;

AGING; ANIMALS; ANIMALS, SUCKLING; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CLARITHROMYCIN; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; ERYTHROMYCIN; HAEMOPHILUS INFLUENZAE; KETOLIDES; LUNG; MACROLIDES; MICE; PNEUMONIA, BACTERIAL; TISSUE DISTRIBUTION;

EID: 0036711425     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(02)00176-0     Document Type: Article

References (22)

1. Kilbourn J.P., Haas H., Morris J.F., Samson S. Hemophilus influenzae biotypes and chronic bronchitis. Am. Rev. Respir. Dis. 128:(6):1983;1093-1094.
2. Farley M.M., Stephens D.S., Harvey R.C., Sikes R.K., Wenger J.D. Incidence and clinical characteristics of invasive Haemophilus influenzae disease in adults. CDC Meningitis Surveillance Group. J. Infect. Dis. 165:(Suppl 1):1992;S42-S43.
3. Blondeau J.M., Suter M., Borsos S. Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococus pneumoniae and Moxarella catarrhalis. Canadian Antimicrobial Study Group. J. Antimicrob. Chemother. 43:(Suppl. A):1999;25-30.
4. Slater L.N. A rat model of prolonged pulmonary infection due to nontypable Haemophilus influenzae. Am. Rev. Respir. Dis. 142:(6 Pt. 1):1990;1429-1435.
5. Acar J.F. Resistance patterns of Haemophilus influenzae. J. Chemother. 11:(Suppl 1):1999;44-50.
6. Zubkov M.N., Gugutsidze E.N., Noniko V.E., Sutormina T.M., Lipkina S.I. Role of Streptococcus pneumoniae and Haemophilus influenzae in the etiology of acute pneumonias in the elderly. Zhurnal Mikrobiol. Epidemiol. Immunobiol. 4:1984;67-70.
7. Gleckman RA, Roth RM. Drug resistant H. influenzae: a growing geriatric problem. Geriatrics 1984;39(9):51-3, 56-8, 60.
8. Mehtar S., Law C.A. An outbreak of beta-lactamase producing Haemophilus influenzae (biotype III) on a geriatric ward. J. Hosp. Infect. 1:(4):1980;357-358.
9. Granoff D.M., Basden M. Haemophilus influenzae infections in Fresno County, California: a prospective study of the effects of age, race, and contact with a case on incidence of disease. J. Infect. Dis. 141:(1):1980;40-46.
10. Bootma H.J., Troelstra A., van Veen-Rutgers A., Mooi F.R., de Neeling A.J., Overbeek B.P. Isolation and characterization of a ciprofloxacin-resistant isolate of Haemophilus influenzae from the Netherlands. J. Antimicrob. Chemother. 39:(2):1997;292-293.
11. Thornsberry C., Jones M.E., Hickey M.L., Mauriz Y., Kahn J., Sahm J. Resistance surveillence of Streptococcus pneumoniae, Hemophilus influenzae and Moxarella catarrhalis isolated in the United States, 1997-1998. J. Antimicrob. Chem. 44:1999;749-759.
12. Carbon C., Poole M.D. The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data. J. Chemother. 11:(2):1999;107-118.
13. Denis A., Agouridas C., Auger J.M., et al. Synthesis and antibacterial activity of HMR 3647, a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. Bioorgan. Med. Chem. Lett. 9:(21):1999;3075-3080.
14. Agouridas C, Denis A, Auger, JM et al. Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and susceptible respiratory pathogens. J Med Chem 1998;41(21):4080-4100.
15. Bieden D.J., Barrett M.S., Jones R.S. Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moxarella catarrhalis strains. Diagn. Microbiol. Infect. Dis. 31:(2):1998;349-353.
16. Bonnefoy A., Guitton M., Delachaume C., Le Priol P., Girard A.M. In vivo efficaaacy of the new ketolide Telithrromycin (HMR 3647) in murine infection models. Antimicrob. Agents Chemother. 45:(6):2001;1688-1692.
17. Esposito A.L., Pennigton J.E. Experimental pneumonia due to Haaaeeemophilus infuluenzae: observations on pathogenesis and treatment. J. Infect. Dis. 149:(5):1984;728-734.
18. Vallee E, Azzoulaay-Dupuis E, Pocidalo JJ, Beerezin EB. Aactivity and locaaal delivery of azithromycin in a mouse model of Haeemophilus influenzae lung infection. Antimicrob Agents Chemother 1992;36(7):1412-1417.
19. Piper K.E., Rouse M.S., Steckelberg J.M., Wilson W.R., Patel R. Ketolide treatment of Haemophilus influenzae experimental pneumonia. Antimicrob. Agents Chemother. 43:(3):1999;708-710.
20. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility for bacteria that grow aerobically. 4th edition. Approved standard NCCLS document M7-A4. NCCLS, Wayne, Pennsylvania, USA, 1997.
21. Miossec-Bartoli C., Pilatre L., Peyrone P., et al. The new ketolide HMR 3647 accumulates in Azurophil granules of human polymorphonuclear cells. Antimicrob. Agents Chemother. 43:1999;2457-2462.
22. Vazifeh D., Preira A., Bryskier A., Labro M.T. Interactions between HMR 3647, a new ketolide, and human polymorphonuclear leukocytes. Antimicrob. Agents Chemother. 42:1998;1944-1951.